| 2015-LOW-67195 | |
| Current research on healing bone fractures either focuses on localized application of a nontargeted bone anabolic agent or a systematic administration of a nontargeted bone anabolic agent that have off-target effects. Both methods lack the desired efficiency and effectivity to treat bone fractures. Researchers at Purdue University have developed a targeted bone anabolic agent capable of accelerated fracture healing. By using a construct that self-assembles into micelles, the technology targets bone fractures to a greater extent than healthy bone, releases drug under physiological conditions, and accelerates fracture healing. This technology utilizes a nontoxic acidic oligopeptide that increases accumulation of the drug in fractures, reduces the accumulation in healthy tissue, and uses a cleavable linker to extend the release of the drug in the fracture site, resulting in faster fracture healing. Advantages -Nontoxic acidic oligopeptide increases accumulation of the drug in fractures and decreases drug accumulation in healthy tissue. Potential Applications: -Medical/Health -Orthopedics -Pharmaceuticals |
|
|
|
|
Jul 13, 2020
CON-Gov. Funding
United States
11,623,009
Apr 11, 2023
Jan 31, 2019
CON-Patent
United States
10,744,203
Aug 18, 2020
Nov 29, 2017
NATL-Patent
United States
10,279,044
May 7, 2019
May 29, 2016
PCT-Patent
WO
(None)
(None)
May 29, 2015
Provisional-Patent
United States
(None)
(None)
(None)
NATL-Patent
Japan
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
